RLMD
Relmada Therapeutics Inc

1,926
Mkt Cap
$334.4M
Volume
276,683.00
52W High
$5.12
52W Low
$0.2404
PE Ratio
-2.54
RLMD Fundamentals
Price
$4.56
Prev Close
$4.60
Open
$4.59
50D MA
$4.12
Beta
0.48
Avg. Volume
540,924.50
EPS (Annual)
-$2.65
P/B
15.99
Rev/Employee
$0.00
$29.22
Loading...
Loading...
News
all
press releases
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders PR Newswire VANCOUVER, BC, Feb. 26, 2026...
PR Newswire·3d ago
News Placeholder
More News
News Placeholder
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Rating of "Hold" from Analysts
Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) have been given an average recommendation of "Hold" by the five research firms that are covering the company, Marketbeat.com...
MarketBeat·7d ago
News Placeholder
Relmada Therapeutics (NASDAQ:RLMD) Trading Up 6.9% - Here's Why
Relmada Therapeutics (NASDAQ:RLMD) Trading Up 6.9% - Should You Buy...
MarketBeat·10d ago
News Placeholder
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Given Average Rating of "Hold" by Analysts
Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) has been assigned an average rating of "Hold" from the five analysts that are presently covering the stock, MarketBeat reports. One...
MarketBeat·1mo ago
News Placeholder
Relmada Therapeutics (NASDAQ:RLMD) Upgraded by Leerink Partners to Outperform Rating
Leerink Partners upgraded Relmada Therapeutics from a "market perform" rating to an "outperform" rating and set a $8.00 price target on the stock in a report on Friday...
MarketBeat·1mo ago
News Placeholder
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Short Interest Update
Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totaling 980,736...
MarketBeat·2mo ago
News Placeholder
Relmada Therapeutics (NASDAQ:RLMD) Stock Rating Upgraded by Jefferies Financial Group
Jefferies Financial Group raised Relmada Therapeutics to a "strong-buy" rating in a report on Monday...
MarketBeat·2mo ago
News Placeholder
Relmada Therapeutics (NASDAQ:RLMD) CFO Maged Shenouda Acquires 11,665 Shares
Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) CFO Maged Shenouda purchased 11,665 shares of the firm's stock in a transaction on Monday, December 15th. The stock was acquired at an...
MarketBeat·2mo ago
News Placeholder
Relmada Therapeutics (NASDAQ:RLMD) CFO Buys $48,059.80 in Stock
Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) CFO Maged Shenouda bought 11,665 shares of the stock in a transaction that occurred on Monday, December 15th. The stock was bought at an...
MarketBeat·3mo ago
News Placeholder
Relmada Therapeutics (NASDAQ:RLMD) Announces Earnings Results
Relmada Therapeutics (NASDAQ:RLMD - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of...
MarketBeat·4mo ago
<
1
2
...
>

Latest RLMD News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.